GRI Bio Reports Positive Phase 2a Results for GRI-0621 with No Severe Adverse Events Over 12 Weeks
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 22 hour ago0mins
- Safety Validation: GRI-0621 demonstrated no drug-related severe adverse events over a 12-week treatment period, with no increase in gastrointestinal issues compared to existing treatments, indicating a safer therapeutic option for IPF patients.
- Biomarker Improvement: Subjects treated with GRI-0621 showed improvements in collagen turnover biomarkers, suggesting fibrosis resolution and alveolar basement membrane repair, potentially providing a new biological basis for IPF treatment.
- Lung Function Enhancement: At 12 weeks, 39% of GRI-0621 treated subjects experienced an increase in forced vital capacity (FVC), while 80% of the placebo group saw a decline, highlighting GRI-0621's potential to improve lung function and alter the treatment landscape for IPF.
- Clinical Advancement Signal: The positive results for GRI-0621 provide a compelling early signal of its disease-modifying potential in IPF, which could create significant value for both patients and shareholders, positioning the company for advancement to the next development stage.
GRI.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on GRI
Wall Street analysts forecast GRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRI is 22.50 USD with a low forecast of 10.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.210
Low
10.00
Averages
22.50
High
35.00
Current: 1.210
Low
10.00
Averages
22.50
High
35.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$10
2025-04-14
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$10
2025-04-14
Reiterates
Strong Buy
Reason
See All Ratings
About GRI
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?